PAC Med Biotech and Kezzler AS will present seminars in Mumbai and Delhi throughout 2009 to promote Kezzler's DME technology for combating counterfeit pharmaceutical and consumer goods. Kezzler's has garnered extremely positive reviews and interest in their technology by leading Indian companies. Read the article. The Confederation of Indian Industry (CII) has just published a book on anti-counterfeiting technologies, in which Kezzler's DME technology receives top reviews and is judged to be ideally suited for India. [Download CII Manual].

A major breast cancer study in India that was set up by PAC Med Biotech on behalf of DiaGenic ASA was completed on schedule. PAC Med Biotech has now successfully coordinated the business entry of DiaGenic's blood-based breast cancer screening and diagnostic test through a tie-up with SRL Ranbaxy, the largest diagnostic laboratory chain in India for a planned launch in Fall 2008. Read the press release.

PAC Med Biotech has been appointed as the Indian partner to Aqua Bio Technology ASA for introduction of their skin care products that use a novel enzyme, zonase. PAC Med Biotech is currently in talks with major companies for marketing and distribution of ABT products. Visit the Aqua Bio Technology site.

PAC Med Biotech has secured a recent licensing opportunity in India for the Cervidil® vaginal insert on behalf of its client Controlled Therapeutics Ltd. This product delivers dinoprostone (a cervical ripener) via a unique, patent-protected delivery system currently used in many countries around the world. More information ...

PAC Med Biotech is reviewing licensing opportunities in India for the Chlamydia rapid test developed by Diagnostics for the Real World (USA). The DRW test provides instant results and is inexpensive compared to other tests, making it ideal for point-of-care testing in resource-limited settings.

Copyright © 2008 PAC Med Biotech Pvt. Ltd. All rights reserved.

[Home]

[Privacy Policy]

[Executive Summary]

[Site PDF]